Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia

被引:15
|
作者
Maki, K. C. [1 ,2 ]
Carson, M. L. [3 ]
Miller, M. P. [3 ]
Anderson, W. H. K. [3 ]
Turowski, M. [3 ]
Reeves, M. S. [1 ]
Kaden, V. [2 ]
Dicklin, M. R. [2 ]
机构
[1] Provident Clin Res & Consulting Inc, Glen Ellyn, IL 60137 USA
[2] Provident Clin Res & Consulting Inc, Bloomington, IN USA
[3] Dow Chem Co USA, Midland, MI 48674 USA
关键词
hydroxypropylmethylcellulose; hypercholesterolemia; statin; soluble dietary fiber; cholesterol; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN-CHOLESTEROL; MOLECULAR-WEIGHT HYDROXYPROPYLMETHYLCELLULOSE; DIETARY FIBER; SERUM-LIPIDS; BLOOD CHOLESTEROL; RANDOMIZED-TRIAL; LDL CHOLESTEROL; THERAPY; VISCOSITY;
D O I
10.1038/ejcn.2009.9
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Consumption of hydroxypropylmethylcellulose (HPMC), a viscous dietary fiber, lowers total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). However, HPMC had not previously been studied in individuals receiving lipid drug therapy. Subjects/Methods: This randomized, double-blind crossover trial examined the lipid effects of HPMC in subjects with hypercholesterolemia on statin therapy. Men (n=5) and women (n=8) with LDL-C >= 2.59 mmol/l after at least 4 weeks of stable-dose statin therapy, and a mean age of 58.6 years, were enrolled. Subjects received twice daily doses of either 2.5 g HPMC or control, delivered in a lemonade beverage for 4 weeks, then crossed over to receive the opposite treatment for an additional 4 weeks. Results: Mean baseline concentrations of TC, non-high-density lipoprotein cholesterol (non-HDL-C), LDL-C, HDL-C, triglyceride (TG), TC/HDL-C ratio and apolipoprotein (Apo) B were 4.95, 3.63, 3.03, 1.33, 1.30 and 3.89 mmol/l and 1.00 g/l, respectively. HPMC consumption resulted in significantly larger reductions (P<0.01 vs control for all) in TC (-10.9 vs -3.5%), non-HDL-C (-12.8 vs -2.9%), LDL-C (-15.7 vs -5.1%), TC/HDL-C ratio (-5.3 vs +1.3%) and Apo B (-8.7 vs -3.9%). There were no differences between treatments for changes in HDL-C (-5.2 vs -4.3%) or TG (+3.9 vs +8.9%). Conclusions: These results support the view that HPMC is an effective adjunct to statin therapy for further lowering atherogenic lipids and lipoproteins in men and women with primary hypercholesterolemia. European Journal of Clinical Nutrition (2009) 63, 1001-1007; doi: 10.1038/ejcn.2009.9; published online 11 February 2009
引用
收藏
页码:1001 / 1007
页数:7
相关论文
共 50 条
  • [21] Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease
    Elshazly, Mohamed B.
    Mani, Preethi
    Nissen, Steven
    Brennan, Danielle M.
    Clark, Donald, III
    Martin, Seth
    Jones, Steven R.
    Quispe, Renato
    Donnellan, Eoin
    Nicholls, Stephen J.
    Puri, Rishi
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (10) : 1091 - 1100
  • [22] Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goalApplication to Germany, Spain and Norway
    John R. Cook
    Don Yin
    Evo Alemao
    Glenn Davies
    Karl J. Krobot
    Enrico Veltri
    Leslie Lipka
    Xavier Badia
    PharmacoEconomics, 2004, 22 : 49 - 61
  • [23] Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
    Johannesen, Camilla Ditlev Lindhardt
    Mortensen, Martin Bodtker
    Langsted, Anne
    Nordestgaard, Borge Gronne
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (11) : 1439 - 1450
  • [24] Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial
    Qin, Xiao Fei
    Zhao, Luo Sha
    Chen, Wei Ren
    Yin, Da Wei
    Wang, Hao
    CLINICAL NUTRITION, 2015, 34 (02) : 201 - 206
  • [25] Non-HDL cholesterol and residual risk of myocardial infarction and death in statin-treated patients with and without diabetes
    Hansen, M. K.
    Mortensen, M. B.
    Olesen, K. K. W.
    Thrane, P.
    Maeng, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [26] Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol in statin-treated patients with coronary artery disease
    Javorsky, M.
    Gasperikova, D.
    Ukropec, J.
    Sedlakova, B.
    Riecansky, I.
    Krizanova, O.
    Sebokova, E.
    Dobrikova, M.
    Klimes, I.
    Tkac, I.
    DIABETOLOGIA, 2007, 50 : S511 - S511
  • [27] Consumption of oat milk for 5 weeks lowers serum cholesterol and LDL cholesterol in free-living men with moderate hypercholesterolemia
    Önning, G
    Wallmark, A
    Persson, M
    Åkesson, B
    Elmståhl, S
    Öste, R
    ANNALS OF NUTRITION AND METABOLISM, 1999, 43 (05) : 301 - 309
  • [28] Plant stanol esters lower LDL cholesterol level in statin-treated subjects with type 1 diabetes by interfering the absorption and synthesis of cholesterol
    Hallikainen, Maarit
    Kurl, Sudhir
    Laakso, Markku
    Miettinen, Tatu A.
    Gylling, Helena
    ATHEROSCLEROSIS, 2011, 217 (02) : 473 - 478
  • [29] Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal - Application to Germany, Spain and Norway
    Cook, JR
    Yin, D
    Alemao, E
    Davies, G
    Krobot, KJ
    Veltri, E
    Lipka, L
    Badia, X
    PHARMACOECONOMICS, 2004, 22 (Suppl 3) : 49 - 61
  • [30] CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction
    Regieli, Jakub J.
    Jukema, J. Wouter
    Grobbee, Diederick E.
    Kastelein, John J. P.
    Kuivenhoven, Jan Albert
    Zwinderman, Aeilko H.
    van der Graaf, Yolanda
    Bots, Michiel L.
    Doevendans, Pieter A.
    EUROPEAN HEART JOURNAL, 2008, 29 (22) : 2792 - 2799